Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020 Jun; 181(2):391-401.

View in: PubMed

subject areas

Adult
Biomarkers, Tumor
Breast Neoplasms
Carcinoma, Ductal, Breast
Carcinoma, Lobular
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Middle Aged
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Peptide Fragments
Prognosis
Prospective Studies
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Single-Blind Method
Survival Rate
Vaccines, Subunit

authors with profiles

JENNIFER LITTON
ELIZABETH ANN MITTENDORF